Showing results (31-40 of 183) with videos related to
Sort By:
Pageof 19
Blood Advances|February 11, 2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutationsTheodore C Tarver, Jason E Hill, Leena Rahmat, et al.Current Oncology Reports|September 3, 2010
Targeted signal transduction therapies in myeloid malignanciesEmma Scott, Elizabeth Hexner, Alexander Perl, et al.Blood|February 28, 2002
TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycleJamil Dierov, Qing Xu, Raia Dierova, et al.Seminars in Hematology|November 14, 2024
A line in shifting sand: Can we define and target TP53 mutated MDS?Sarah Skuli, Andrew Matthews, Martin Carroll, et al.Cancer Cell|February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutaratePatrick S Ward, Jay Patel, David R Wise, et al.Expert Review of Proteomics|September 25, 2015
Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigationsÖzlem Önder, Simone Sidoli, Martin Carroll, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.Cancer Cell|September 13, 2011
Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemiaGerd A Blobel, Anna Kalota, Patricia V Sanchez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Intrinsic resistance to JAK2 inhibition in myelofibrosisAnna Kalota, Grace R Jeschke, Martin Carroll, et al.The Lancet. Haematology|October 23, 2021
Harnessing the benefits of available targeted therapies in acute myeloid leukaemiaHagop Kantarjian, Nicholas J Short, Courtney DiNardo, et al.Pageof 19